Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 7/20 | 0.62 |
| ▸ | CPA3 | P15088 | 3/20 | 0.62 |
| ▸ | CPB1 | P15086 | 1/20 | 0.62 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | MME | P08473 | 3/20 | 0.58 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | ANPEP | P15144 | 1/20 | 0.51 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.51 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1244653 | 0.90 | MEN1 (0.55) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL28567505 | 0.89 | SLC15A1 (0.50) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL11815481 | 0.86 | SLC15A1 (0.48) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL16568776 | 0.85 | SLC15A1 (0.72) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL14540434 | 0.85 | CPA1 (0.55) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL28675003 | 0.85 | MMP8 (0.46) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL5552886 | 0.84 | F2 (0.52) | SLC15A1 | |
| SCHEMBL9574107 | 0.83 | CPA1 (0.66) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL7505398 | 0.83 | CPA1 (0.66) | CPA1CPA3CPB1CPB2CYP1A2 | |
| SCHEMBL18065659 | 0.83 | MMP8 (0.53) | CYP1A2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504382-B2 | Protease inhibitors for coronaviruses and SARS-CoV and the use thereof | CYTOVIA, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504382-B2 | Protease inhibitors for coronaviruses and SARS-CoV and the use thereof | CYTOVIA, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080300191-A1 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC. | 2008-12-04 | — | — | US | disclosed |
| US-20080300191-A1 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC. | 2008-12-04 | — | — | US | disclosed |
| WO-2004101742-A2 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC (US) | 2004-11-25 | — | — | WO | disclosed |
| US-4738803-A | ENZYME INHIBITORS | ROQUES BERNARD (FR) | 1988-04-19 | — | — | US | disclosed |
| US-4618708-A | ENKEPHALINASE INHIBITOR, ANALGESICS, ANTIDEPRESSANT, ANTIDIARRHEA, OR HYPOTENSIVE AGENT | ROQUES BERNARD (FR) | 1986-10-21 | — | — | US | disclosed |
| US-4464392-A | Process for controlling antimicrobial activity using glycolic acid derivatives | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1984-08-07 | — | — | US | disclosed |
| EP-0038046-B1 | PHARMACEUTICAL AMIDES, AND PREPARATION, FORMULATIONS AND USE THEREOF | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-02-29 | — | — | EP | disclosed |
| EP-0038046-A2 | Pharmaceutical amides, and preparation, formulations and use thereof | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300191-A1 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | ACE, ACE2, TMPRSS2 | CPA1 31/4885CPA3 62/4885CPB1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.